Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-11

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In recent years, endocytoscopy (EC) has undergone rapid development as an advanced endoscopic technique. Characterized by real-time histological imaging and detection capabilities, EC enables visualization of living cells in the digestive mucosal layer through methylene blue staining via the endoscopic instrument channel. This technology provides ultra-magnified endocytoscopic images, allowing for identification of key cellular features including epithelial cell morphology and the shape of methylene blue-stained epithelial nuclei, thereby facilitating clear in vivo observation of microstructural characteristics in mucosal tissues - a technique commonly referred to as "optical biopsy". However, current clinical application of EC in China remains limited due to insufficient practical experience and the absence of standardized diagnostic criteria for image interpretation. This study aims to comprehensively evaluate the diagnostic accuracy of domestically developed high-magnification electronic upper gastrointestinal endoscopy for esophageal carcinoma and precancerous lesions, using histopathology as the gold standard. The research objectives include establishing standardized diagnostic evaluation protocols and clarifying the clinical value of this technology through systematic validation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions

NCT01508520

Stomach Neoplasms

COMPLETED

Comparison of Diagnostic Accuracies of Various Endoscopic Examination Techniques

NCT03109938

Colorectal Cancer

UNKNOWN

Narrow Band Imaging (NBI) Against Lugol for Squamous Esophageal Cancer

NCT02002559

Superficial Esophageal Neoplasia

COMPLETED

A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions

NCT02968069

Early Gastric Cancer

NOT_YET_RECRUITING NA

Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD

NCT07088744

Gastric Cancer (Diagnosis) Gastric High-grade Intraepithelial Neoplasia Gastric Low-grade Intraepithelial Neoplasia +1 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer, Squamous Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1.Patients diagnosed with superficial esophageal squamous cell carcinoma or high-grade intraepithelial neoplasia (HGIN) through endoscopic and pathological biopsy examinations, scheduled for endoscopic submucosal dissection (ESD); 2.Patients with esophageal squamous low-grade intraepithelial neoplasia (LGIN) confirmed by endoscopic and biopsy histopathological examinations within the preceding six months; 3. Patients exhibiting esophageal focal lesions detected during painless upper gastrointestinal endoscopy requiring pathological biopsy.

Exclusion Criteria

1. Patients aged \<18 years or \>80 years;
2. Lesions located at the gastroesophageal junction with clinical suspicion of adenocarcinoma or precancerous lesions;
3. Patients with contraindications to sedated/anesthetized upper gastrointestinal endoscopy;
4. Patients with coagulation disorders;
5. Patients with a history of hypersensitivity to relevant medications (including anesthetics or methylene blue);
6. Patients presenting dysphagia or gastrointestinal obstructive symptoms, or those with suspected/confirmed digestive tract obstruction, stenosis, or fistulae;
7. Patients declining to provide informed consent for study participation, or any other circumstances deemed by investigators to preclude eligibility.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No